Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6IRN4)

Drug Name
[3H]RX821002 Drug Info
Synonyms
2-Methoxyidazoxan; RX-821002; RX 821002; 102575-24-6; RX821002; alpha-methoxyidazoxan; RX 821001; CHEMBL10332; CHEBI:73287; 2-(2,3-Dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; 1H-Imidazole, 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-; 2-[2-(2-methoxy-1,4-benzodioxanyl)]imidazoline; 2-(2-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; [3H]2-methoxyidazoxan; 2-(2-methoxy-3H-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; 2-ethoxy-idazoxan; PubChem2676; Spectrum_001808; [3H]2-methoxyidazoxan
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
108094
ChEBI ID
CHEBI:73287
CAS Number
CAS 102575-24-6
TTD Drug ID
DM6IRN4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [5]
Dihydroergocristine DM5SQ1G Alcohol dependence 6C40.2 Approved [6]
Brimonidine DMQLT4N Ocular hypertension 9C61.01 Approved [7]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [8]
Amezinium DM6I2WQ Hypotension BA20-BA21 Approved [9]
Propylhexedrine DMTBW2O Obesity 5B81 Approved [10]
Tetrahydrozoline DMT57WC Ocular disease 1F00.1Z Approved [11]
Rilmenidine DM13PQW Hypertension BA00-BA04 Approved [12]
Xylometazoline DMKV32D Allergic rhinitis CA08.0 Phase 4 [4]
TNX-102 DMO1234 Fibromyalgia MG30.01 Phase 3 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [14]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [5]
Connexyn DMF29Q5 Attention deficit hyperactivity disorder 6A05.Z Approved [15]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [16]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [17]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [18]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [19]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [20]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [21]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methamphetamine DMPM4SK Anxiety Approved [23]
Propericiazine DME9JNL Psychiatric disorder 6E8Z Approved [24]
Methoxamine DMF5XQH Hypertension BA00-BA04 Approved [25]
Phendimetrazine DM6TS1N Obesity 5B81 Approved [26]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [18]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [27]
Sunepitron DM6M8ZX N. A. N. A. Discontinued in Phase 3 [28]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [20]
SOU-001 DMPAEK5 Urinary incontinence MF50.2 Discontinued in Phase 2 [29]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-2B (ADRA2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [5]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [18]
AGN-199981 DMP5Y1A Neuropathic pain 8E43.0 Phase 2 [31]
INDORAMIN DMNSJFD Hypertension BA00-BA04 Withdrawn from market [32]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [20]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [22]
A-80426 DMBC3DG N. A. N. A. Terminated [33]
WB-4101 DMQU8B1 N. A. N. A. Terminated [34]
SK&F-104078 DMRADBU N. A. N. A. Terminated [32]
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [35]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxazosin DM9PLRH Benign prostatic hyperplasia GA90 Approved [36]
Armodafinil DMGB035 Malignant glioma 2A00.0 Approved [37]
Alfuzosin DMZVMKF Benign prostatic hyperplasia GA90 Approved [38]
Moxisylyte DMFCLYW Erectile dysfunction HA01.1 Approved [39]
Terazosin DM3JCVS Benign prostatic hyperplasia GA90 Approved [40]
Bunazosin DM4I8O7 Glaucoma/ocular hypertension 9C61 Approved [41]
Trimazosin DM1QLST Congestive heart failure BD10 Approved [42]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [18]
DL-017 DMM8GZT Hypertension BA00-BA04 Phase 1 [43]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [45]
NAFTOPIDIL DMQ8R4E Hypertension BA00-BA04 Approved [45]
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [46]
Xatral DMLHOA0 Benign prostatic hyperplasia GA90 Approved [47]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [48]
Besipirdine DMLVNTA Cognitive impairment 6D71 Phase 3 [49]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [18]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [44]
PMID30124346-Compound-LDT66 DMJMTNL Benign prostatic hyperplasia GA90 Patented [44]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Alpha-2C adrenergic receptor (ADRA2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [50]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [51]
Oxymetazoline DM8ZXT6 Arrhythmia BC9Z Approved [4]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [52]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [53]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [54]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [55]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [56]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [57]
Xylometazoline DMKV32D Allergic rhinitis CA08.0 Phase 4 [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Alpha-2A adrenergic receptor (ADRA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [58]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [59]
Rilmenidine DM13PQW Hypertension BA00-BA04 Approved [60]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [61]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [62]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [63]
Oxymetazoline DM8ZXT6 Arrhythmia BC9Z Approved [4]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [64]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [52]
Indapamide DMGN1PW Edema MG29 Approved [65]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Alpha-2B adrenergic receptor (ADRA2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [66]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [52]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [58]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [67]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [68]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [69]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [70]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-1A (ADRA1A) TTNGILX ADA1A_HUMAN Inhibitor [2]
Adrenergic receptor alpha-1B (ADRA1B) TTBRKXS ADA1B_HUMAN Inhibitor [2]
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Inhibitor [2]
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Inhibitor [2]
Adrenergic receptor alpha-2B (ADRA2B) TTWM4TY ADA2B_HUMAN Antagonist [3]
Adrenergic receptor alpha-2C (ADRA2C) TT2NUT5 ADA2C_HUMAN Antagonist [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alpha-2A adrenergic receptor (ADRA2A) OTZFGOTP ADA2A_HUMAN Drug Response [4]
Alpha-2B adrenergic receptor (ADRA2B) OTLJKGSE ADA2B_HUMAN Drug Response [4]
Alpha-2C adrenergic receptor (ADRA2C) OT5B9RKP ADA2C_HUMAN Drug Response [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 528).
2 Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. J Med Chem. 1986 Oct;29(10):2000-3.
3 Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs. Eur J Pharmacol. 1994 Jan 24;252(1):43-9.
4 Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
5 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
6 Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
8 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
9 Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
10 Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
11 Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
12 Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
13 Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
14 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
15 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
16 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
17 Clinical pipeline report, company report or official report of Klus Pharma
18 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
21 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
22 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
23 Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
24 Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
25 Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
26 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
27 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
28 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
29 Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
30 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
31 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
32 Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
33 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
34 alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
35 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
36 The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
37 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
38 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
39 Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
40 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
41 Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
42 The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
43 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
44 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
45 Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
46 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
47 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
48 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
49 Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
50 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
51 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
52 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
53 Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
54 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
55 Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
56 Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011 Apr;84(4):801-15.
57 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
58 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
59 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
60 Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126(6):1522-30. doi: 10.1038/sj.bjp.0702429.
61 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
62 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
63 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
64 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
65 Platelet alpha 2-adrenoceptor modifications induced by long-term treatment with indapamide in essential hypertension. Am J Med. 1988 Jan 29;84(1B):31-5.
66 Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
67 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
68 Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
69 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
70 Bisphenol A and bisphenol S induce distinct transcriptional profiles in differentiating human primary preadipocytes. PLoS One. 2016 Sep 29;11(9):e0163318.